# Outcomes of six dogs with prostate carcinoma and bacterial prostatitis treated with prostate artery embolization

**Authors:** Kornelia Tiffinger, Erin Gibson, Dana L Clarke, William T N Culp, Carrie Palm, Christopher Thomson

PMC · DOI: 10.1093/jvimsj/aalag034 · Journal of Veterinary Internal Medicine · 2026-03-06

## TL;DR

This study examines the outcomes of six dogs with prostate cancer and bacterial prostatitis treated with artery embolization, finding that infections were not life-threatening.

## Contribution

The study is the first to report outcomes of prostate artery embolization in dogs with concurrent prostate cancer and bacterial prostatitis.

## Key findings

- Only a minority of dogs developed urinary tract infections or bacterial prostatitis after treatment.
- Median survival was 13 months with no deaths from infection.
- Prostate artery embolization is feasible in dogs with concurrent prostate cancer and bacterial prostatitis.

## Abstract

Risk of recurrent lower urinary tract infection and bacterial prostatitis (BP) after prostate artery embolization in dogs diagnosed with concurrent BP and prostatic carcinoma (PC) is unknown.

To report short- and long-term outcomes of dogs with PC and BP undergoing prostatic artery embolization (PAE).

Six clients owned dogs with a concurrent diagnoses of BP and PC that subsequently underwent PAE and had a minimum follow-up of 4 months after PAE.

Medical records of 6 dogs diagnosed with PC and BP and treated with PAE were retrospectively reviewed. Physical exams, clinicopathologic and imaging results, procedural details, and short- and long-term outcome data were evaluated.

Prostatic carcinoma was diagnosed via imaging findings (6/6), cadet-B-Raf protein (BRAF) testing (3/6), ultrasound-guided aspirates (2/6), and cystoscopic biopsy (1/6). BP was diagnosed based on clinical signs (6/6), imaging (6/6), urinalysis and positive urine culture (6/6), and concurrent positive prostatic wash cultures (2/6). All dogs received antibiotics based on urine culture and sensitivity testing (UCS) for a median of 7 weeks (range 2-13) before PAE. Two dogs had positive UCS at the time of PAE. One dog developed a prostatic abscess and 2/6 had positive UCS after PAE. Median survival was 13 months (4.5-17), and no dog died from infection.

Urinary tract infection, BP, or a combination of both occurred in a minority of dogs undergoing PAE in this cohort and were not life-limiting complications. In dogs, concurrent BP and PC should not prevent treatment with PAE.

## Linked entities

- **Proteins:** BRAF (B-Raf proto-oncogene, serine/threonine kinase)
- **Diseases:** prostate carcinoma (MONDO:0005159)
- **Species:** Canis lupus familiaris (taxon 9615)

## Full-text entities

- **Genes:** ALPL (alkaline phosphatase, biomineralization associated) [NCBI Gene 403548] {aka ALP}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 475526]
- **Diseases:** urinary incontinence (MESH:D014549), urinary tract (MESH:D014570), ureteral obstruction (MESH:D014517), pyuria (MESH:D011776), PAE (MESH:D011472), embolic (MESH:D004617), hypercholesteremia (MESH:D006937), infection (MESH:D007239), peritoneal effusion (MESH:D010538), lethargy (MESH:D053609), UTI (MESH:D014552), E. coli infection (MESH:D004927), BPH (MESH:D011470), anemia (MESH:D000740), hypocalcemia (MESH:D006996), prostatic disease (MESH:D011469), metastasis (MESH:D009362), urinary tract tumors (MESH:D014571), death (MESH:D003643), neutrophilia (MESH:C563010), bacterial colonization (MESH:D015179), vomiting (MESH:D014839), lymphadenopathy (MESH:D008206), diarrhea (MESH:D003967), hypoalbuminemia (MESH:D034141), cancer (MESH:D009369), ischemic (MESH:D002545), pulmonary metastatic (MESH:D000092182), steatitis (MESH:D013231), hepatic abscesses (MESH:D008100), abscess (MESH:D000038), inflammation (MESH:D007249)
- **Chemicals:** ampicillin sodium/sulbactam sodium (MESH:C035444), prednisone (MESH:D011241), steroids (MESH:D013256), meloxicam (MESH:D000077239), cefazolin (MESH:D002437), BP (-), Carboplatin (MESH:D016190), Mitoxantrone (MESH:D008942), methicillin (MESH:D008712), clindamycin (MESH:D002981), meropenem (MESH:D000077731), piroxicam (MESH:D010894), carprofen (MESH:C007005), trimethoprim/sulfadiazine (MESH:C024873), enrofloxacin (MESH:D000077422)
- **Species:** Homo sapiens (human, species) [taxon 9606], Proteus mirabilis (species) [taxon 584], Staphylococcus pseudintermedius (species) [taxon 283734], Mycoplasmopsis canis (species) [taxon 29555], Streptococcus (genus) [taxon 1301], Canis lupus familiaris (dog, subspecies) [taxon 9615], Escherichia coli (E. coli, species) [taxon 562]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963965/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963965/full.md

---
Source: https://tomesphere.com/paper/PMC12963965